CDC Recommendations and Guidelines, by category
Current CDC guidelines and recommendations for the prevention, treatment, and control of TB are organized into these categories:
These guidelines and recommendations address the obstacles and opportunities for controlling and eliminating TB in the United States, including the essential components of TB prevention and control programs, and the need to address TB in low-incidence areas of the United States and in communities with at-risk minority populations.
These diagnostic standards provide a practical guide and statement of principles for all persons involved in the care of patients with TB. They cover transmission of mycobacterium tuberculosis, clinical manifestations of TB, diagnostic microbiology, tuberculin skin test, definitions of TB disease and latent infection, and treatment of TB and TB infection.
These guidelines update previous CDC recommendations for the diagnosis, treatment, and prevention of TB among adults and children coinfected with HIV in the United States.
These guidelines address populations including correctional, elderly, homeless, and migrant farm workers.
Transmission of mycobacterium tuberculosis is a risk for patients and health care workers in healthcare facilities. These guidelines recommend strategies for reducing this risk in healthcare facilities.
These guidelines cover laboratory services and testing.
Outbreaks of multidrug-resistant TB (MDR) pose a public health problem and require rapid attention. These guidelines present an action plan to specifically address this problem and cover the management of persons exposed to MDR.
These guidelines address the application of genotyping to tuberculosis prevention and control.
Targeted tuberculin testing for latent tuberculosis infection (LTBI) is a strategic component of TB control that identifies persons at high risk for TB who would benefit by treatment of LTBI, if detected. These guidelines provide new recommendations for targeted tuberculin testing and treatment regimens for LTBI. Guidelines are also given to screening for TB and TB infection in high-risk populations.
These guidelines address treatment regimens for TB among adults, children, persons coinfected with HIV, persons exposed to MDR, and LTBI.
These guidelines discuss the role of vaccines in TB prevention and control in the United States. Bacillus of Calmette and Guerin (BCG) vaccine is not recommended for programmatic use in the United States. Recognizing the importance of TB vaccines, the ACET recommends that public agencies and vaccine manufacturers develop a comprehensive strategy for new TB vaccine development.
View a list of all categories for which the CDC has issued guidelines and recommendations for the prevention, treatment, and control of TB.
Featured CDC TB Guidelines and Recommendations
Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis
From CDC's MMWR Recommendations and Reports; October 25, 2013 / 62(rr09);1-12
Availability of an Assay for Detecting Mycobacterium tuberculosis, Including Rifampin-Resistant Strains, and Considerations for Its Use—United States, 2013
From CDC's MMWR Weekly; October 18, 2013 / 62(41);821-824
Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection
From CDC's MMWR Weekly; December 9, 2011 / 60(48);1650-1653
Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection—United States, 2010
From CDC's MMWR Recommendations and Reports; June 25, 2010 / 59(RR05);1-25
Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis
From CDC's MMWR Weekly; January 16, 2009 / 58(01);7-10
Guidelines for Using the QuantiFERON-TB Gold Test for Detecting Mycobacterium tuberculosis Infection, United States
From CDC's MMWR Recommendations and Reports; December 16, 2005; 54(No. RR-15): 49-55.
Plan to Combat Extensively Drug-Resistant Tuberculosis
From CDC's MMWR Recommendations and Reports; February 13, 2009; 58 (RR-03); 1-43
Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis
From Centers for Disease Control and Prevention's (CDC) MMWR Recommendations and Reports: December 16, 2005 / Vol. 54(RR15): 1-37
Controlling Tuberculosis in the United States - Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America
From CDC's MMWR: November 4, 2005 / Vol. 54(RR12): 1-81
Treatment of Tuberculosis
American Thoracic Society, CDC, and Infectious Diseases Society of America
MMWR: June 20, 2003 / Vol. 52 (RR11): 1-77
Progressing Toward Tuberculosis Elimination in Low-Incidence Areas of the United States - Recommendations of the Advisory Council for the Elimination of Tuberculosis
From CDC’s MMWR Recommendations and Reports: May 3, 2002 / Vol. 51 (RR05);1-16
Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings, 2005
From CDC’s MMWR Recommendations and Reports, December 30, 2005 / Vol. 54 (RR17); 1-141
Prevention and Control of Tuberculosis in Correctional and Detention Facilities: Recommendations from CDC
From CDC’s MMWR Recommendations and Reports 2006; July 7, 2006 / Vol. 55 (RR09); 1-44
Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC
From CDC’s MMWR Recommendations and Reports 2005; December 16, 2005 / Vol. 54 (RR15)/ 1-37